10/14/2005 – Antipodean Pharmaceuticals Inc., developer of a clinical compound to treat Parkinson’s disease and Friedrich’s ataxia, has raised $14.5 million in its first institutional financing round, according to a filing with the Securities and Exchange Commission.
